Survodutide posts the first Phase 3 readout for a dual GLP-1/glucagon agonist

Survodutide has posted its first Phase 3 topline results, reporting an average weight loss of 16.6% at 76 weeks compared with 3.2% for placebo in the SYNCHRONIZE-1 trial.^[1] The readout, announced April 28, 2026, marks the first pivotal-trial data point for a dual GLP-1/glucagon agonist, a drug class distinct from the GLP-1-only and GLP-1/GIP combinations already on the market.^[1]

Survodutide's numbers are lower than results reported for two other drugs still in testing. Retatrutide's TRIUMPH-1 trial, which read out about three weeks later on May 21, 2026, showed 28.3% mean weight loss at 80 weeks on the 12 mg dose in a study of 2,339 participants, with weight loss reaching 30.3% at 104 weeks in an extension study of people with a BMI of 35 or higher.^[1] CagriSema, an amylin-plus-GLP-1 combination from Novo Nordisk, is described as the year's main pending regulatory decision, with an FDA review expected to conclude sometime in late 2026 after the company's December 2025 filing.^[1] Survodutide is not currently approved for any use in the United States, and no FDA filing timeline is confirmed in the available information.

The source material also notes a separate body-composition analysis tied to the SYNCHRONIZE-1 program, though details of that analysis are not spelled out.^[1] Survodutide combines GLP-1 receptor activity with glucagon receptor activity, and the glucagon component is intended to target liver fat in addition to overall body weight, according to the development summary. The full trial data, along with results from other pipeline drugs, were slated for presentation at the American Diabetes Association's 2026 scientific sessions, held June 5-8 in New Orleans.^[1]

Why it matters for patients

For people already using or considering an approved GLP-1 drug like Ozempic, Wegovy, Mounjaro, or Zepbound, survodutide is not an option today. It remains in testing, and this is a topline result rather than a full data publication or a regulatory filing. Patients cannot obtain it through a prescription in the United States based on the information available so far.

The 16.6% weight loss figure is useful mainly as a comparison point. It sits below the roughly 28% to 30% weight loss reported for retatrutide's Phase 3 program and below results reported for CagriSema, though the sources do not give a side-by-side placebo-adjusted comparison across all three drugs using identical methods.^[1] Differences in trial length, patient population, and dosing can affect how these numbers compare, and the sources do not detail those factors for survodutide specifically.

The glucagon mechanism is being watched partly because of its potential effect on liver fat, a feature that sets it apart from GLP-1-only drugs. Whether that translates into a meaningful clinical benefit beyond weight loss, and how it compares on safety, is not addressed in the available reporting.

What happens next

Fuller SYNCHRONIZE-1 data, including the body-composition analysis, were expected to be presented at the ADA scientific sessions in New Orleans, June 5-8, 2026.^[1] No FDA submission date for survodutide is confirmed in the sourced material. Separately, CagriSema's FDA decision is expected sometime in late 2026, and retatrutide's manufacturer has not yet confirmed a submission timeline despite strong readouts from its TRIUMPH program.^[1] Patients interested in how survodutide compares with approved options will need to wait for additional published data and, eventually, a regulatory filing before any approval timeline becomes clear.